PineStone Asset Management Inc. Reduces Stake in Johnson & Johnson $JNJ

Key Points

• PineStone Asset Management trimmed its Johnson & Johnson stake by 1.1% in Q4, selling 22,742 shares and now holds 2,067,667 shares (about 0.09% of JNJ) worth roughly $427.9 million, making J&J ~2.7% of PineStone’s portfolio and its 12th largest position.
• Wall Street sentiment is cautiously positive with a consensus rating of “Moderate Buy” and an average price target of $236.91 (1 Strong Buy, 17 Buy, 9 Hold among analysts).
• Insiders have been net sellers, offloading 30,142 shares (~$7.36 million) in the last three months (insiders now own 0.16% of the company), including notable EVP sales disclosed in SEC filings.

PineStone Asset Management Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,067,667 shares of the company's stock after selling 22,742 shares during the period. Johnson & Johnson accounts for approximately 2.7% of PineStone Asset Management Inc.'s portfolio, making the stock its 12th biggest position. PineStone Asset Management Inc. owned about 0.09% of Johnson & Johnson worth $427,904,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of JNJ. LeConte Wealth Management LLC lifted its holdings in Johnson & Johnson by 8.1% in the fourth quarter. LeConte Wealth Management LLC now owns 4,762 shares of the company's stock valued at $986,000 after acquiring an additional 355 shares during the last quarter. My Personal CFO LLC raised its position in Johnson & Johnson by 41.5% in the fourth quarter. My Personal CFO LLC now owns 4,221 shares of the company's stock valued at $874,000 after purchasing an additional 1,238 shares during the period. Nikulski Financial Inc. raised its position in Johnson & Johnson by 56.4% in the fourth quarter. Nikulski Financial Inc. now owns 1,863 shares of the company's stock valued at $385,000 after purchasing an additional 672 shares during the period. ACT Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 3.9% in the 4th quarter. ACT Wealth Management LLC now owns 1,399 shares of the company's stock valued at $290,000 after purchasing an additional 52 shares during the last quarter. Finally, Santori & Peters Inc. grew its holdings in shares of Johnson & Johnson by 3.8% during the 4th quarter. Santori & Peters Inc. now owns 1,450 shares of the company's stock worth $300,000 after purchasing an additional 53 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on JNJ. Wall Street Zen lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. Loop Capital set a $220.00 price target on shares of Johnson & Johnson in a research report on Tuesday, January 27th. Argus upped their price objective on shares of Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. Bank of America reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Monday, March 2nd. Finally, Wolfe Research lifted their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an "outperform" rating in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $236.91.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royalty Pharma signed a $500M R&D deal with J&J to support an experimental autoimmune antibody — a meaningful near‑term collaboration and capital inflow that supports JNJ’s pipeline value. Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal
• Positive Sentiment: New randomized controlled trial data presented at ACC 2026 and published in JACC bolster JNJ’s pharma/MedTech credibility — supports revenue upside from adoption of cardiovascular products. Why Johnson & Johnson (JNJ) Is One of the Best Pharma Stocks to Invest in Now
• Positive Sentiment: Analysts and dividend trackers expect J&J to announce another dividend increase in April, reinforcing its income profile for income‑oriented investors. 7 Dividend Increases Expected In April 2026
• Neutral Sentiment: JNJ has become a trending stock on retail/analysis platforms, increasing attention and trading flows but not necessarily changing fundamentals. Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: JNJ’s history of earnings beats and solid margins keeps expectations elevated; investors will watch the next report closely for confirmation. Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
• Negative Sentiment: MedTech preview notes China weakness as a potential headwind for Q1 MedTech revenue — regional softness could pressure sales versus expectations. JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch
• Negative Sentiment: After a ~61% one‑year rally, some outlets question valuation and whether upside is limited from current levels — valuation concerns can amplify selling on weakness. Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 61% One-Year Surge?
• Negative Sentiment: Bridgewater’s Ray Dalio trimming his JNJ stake was reported — large-manager trimming can be read negatively by some investors even if position sizes are modest. Johnson & Johnson (JNJ): Billionaire Ray Dalio Trims Position

Johnson & Johnson Stock Down 0.0%

Johnson & Johnson stock opened at $242.93 on Friday. The firm has a market capitalization of $585.11 billion, a P/E ratio of 21.98, a P/E/G ratio of 2.41 and a beta of 0.34. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $251.71. The stock's fifty day simple moving average is $239.86 and its 200-day simple moving average is $212.75.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Insider Transactions at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 30,142 shares of company stock valued at $7,360,528. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.